Atrophy / Skin atrophy

• (2020): Niculet E+, Clin Cosmet Investig Dermatol 13, 1041-1050 [REVIEW]

Cushingoid features

• (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

• (2013): Guillot B, Rev Med Interne (French) 34(5), 310-4 [REVIEW]

Hirsutism

• (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Behavioral disturbances / personality changes

• (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Cognitive impairment

• (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Delirium

• (2022): Raso J+, Int J Clin Pharm Jan, Online ahead of print (association)

Depression

• (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
• (2011): Celano CM+, Dialogues Clin Neurosci 13(1), 109 [REVIEW]

Encephalopathy (includes hepatic encephalopathy)

• (2024): McCormick BJ+, BMJ Case Rep May, e255793 (1 case / female) (exacerbation)
• (2015): Gascon-Bayarri J+, Case Rep Neurol Med Apr (e-Collection) (exacerbation)

Insomnia

• (2017): Ismail MF+, Future Oncol [REVIEW]

Mania

• (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Mood changes (includes mood disorder)

• (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Neuropsychiatric / neuropsychological adverse effect

• (2024): Sofía-Avendaño-Lopez S+, Biomedicines 12(9), 2131 [REVIEW]
• (2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]

Neurotoxicity

• (2014): Prescrire Int 23(150), 153 (violent behavior)

Psychiatric adverse effect

• (2025): Seymour N+, Psychooncology 34(4), e70137 [REVIEW]
• (2019): Staub Y+, J Oncol Pharm Pract Oct, Epub ahead of print65–78%

Psychosis

• (2023): Fani-Molky P+, J Child Adolesc Psychopharmacol 33(3), 78-90 [REVIEW]
• (2021): Huynh G+, J Pharm Technol 37(2), 120-126 (13 cases) [REVIEW]
• (2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]

Sleep disturbances

• (2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]

Adrenal insufficiency (hypoadrenalism) / Addisonian crisis (includes Addison's disease)

• (2024): Beuschlein F+, Eur J Endocrinol 190(5), G25-G51 [REVIEW]
• (2024): Qiu Y+, Front Endocrinol (Lausanne) Dec (e-Collection) 14%

Cushing's syndrome

• (2021): Thakran P+, Indian Dermatol Online J 12(2), 237-243 (23 cases)

Diabetes mellitus

• (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

Hyperglycemia (includes glucose increased)

• (2023): Johal JS+, Clin Exp Dermatol Jan, Online ahead of print [REVIEW]
• (2022): Kandil I+, Can J Diabetes Mar, Online ahead of print [REVIEW]
• (2022): Shah P+, Diabetes Metab Syndr Obes 15, 1577-1588
• (2020): Delfs N+, J Clin Med 9(12), E407934%

Hypoglycemia

• (2020): Delfs N+, J Clin Med 9(12), E40794%

Weight gain

• (2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]

Gastrointestinal disorder / discomfort

• (2019): Qian G+, Int Urol Nephrol March, Epub ahead of print [REVIEW]

Pancreatitis / acute pancreatitis

Immunosupression

• (2023): Mustafa SS, Ann Allergy Asthma Immunol Jan, Online ahead of print [REVIEW]

Pheochromocytoma crisis / paraganglioma crisis

• (2018): Geva GA+, Case Rep Endocrinol Feb (e-Collection) (1 case / male) (induction)

Osteonecrosis / avascular necrosis (includes steroid-induced osteonecrosis of the femoral head)

• (2024): Zhai YL+, Curr Med Sci Sep, Online ahead of print (pharmacogenomics)
• (2024): Zhang CM+, Per Med 21(2), 89-102 (pharmacogenomics)
• (2023): Compston JE, Eur J Endocrinol Mar, Online ahead of print [REVIEW]
• (2022): Motta F+, J Transl Autoimmun Sep (e-Collection) [REVIEW]
• (2021): Zgheib NK+, Per Med Aug, Online ahead of print7% (grade 4)

Osteoporosis

• (2025): Grygorieva NV+, Arch Osteoporos 20(1), 31 [REVIEW]
• (2025): Madrid A+, Ther Umsch (German) 82(1), 20-25 [REVIEW]
• (2024): Tanaka Y+, J Bone Miner Metab Mar, Online ahead of print
• (2023): Jha SS, Indian J Orthop 57(Suppl 1), 181-191 [REVIEW]
• (2022): Chen KL+, Cutis 110(4), 201-206
• (2022): Messina OD+, Aging Clin Exp Res Nov, Online ahead of print [REVIEW]
• (2021): Cho SK+, Endocrinol Metab (Seoul) Jun, Online ahead of print [REVIEW]
• (2020): Ward LM, Front Endocrinol (Lausanne) Dec (e-Collection)

Tendinopathy/Tendon rupture

• (2016): Knobloch K, Adv Exp Med Biol 920, 229

Cataract

• (2019): Caban M, Postepy Biochem (Polish) 65(3), 227-230
• (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

Chorioretinopathy

Endophthalmitis

Glaucoma (includes acute angle-closure glaucoma)

• (2024): Jain VK+, Rom J Ophthalmol 68(4), 362-366 (7 cases) (with concomitant medication)
• (2023): Kawabe A+, Pharmaceuticals (Basel) 16(7), 948 (association)
• (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

Ocular hypertension

• (2024): Jain VK+, Rom J Ophthalmol 68(4), 362-366 (9 cases) (with concomitant medication)

Pneumonia

• (2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]

Pulmonary fibrosis

• (2024): McCall KL+, Pharmacoepidemiol Drug Saf 33(5), e5797 (association) (pharmacovigilance / pharmacoepidemiology)

Adverse effects / adverse reactions

• (2021): Ma S+, Signal Transduct Target Ther 6(1), 83 [REVIEW] (passim)
• (2021): Santiago T+, Rheumatology (Oxford) Jan, Online ahead of print [REVIEW]
• (2020): Cheng W+, Front Pharmacol Sep (e-Collection) (mild) [REVIEW] (passim)
• (2020): Sterne JAC+, JAMA Sep, Online ahead of print [REVIEW]

Adverse pregnancy outcomes

• (2025): Laugesen K+, JAMA Netw Open 8(1), e2453245 (association)

Congenital malformations

• (2024): Saarti M+, Georgian Med News (348), 128-131 (association) (orofacial cleft)
• (2007): Carmichael SL+, Am J Obstet Gynecol 197(6), 585.e1-7; discussion 683-4, e1-7 (orofacial cleft)
• (2003): Källén B, Cleft Palate Craniofac J 40(6), 624-8 (orofacial cleft)